Table 3.
Summary of the clinical presentation, endoscopic findings, and treatments.
| Symptoms on presentation, no. of patients (%) | N = 25 |
|---|---|
| Nausea | 20 (80.0) |
| Vomiting | 13 (52.0) |
| Abdominal pain | 18 (72.0) |
| Bloating | 3 (12.0) |
| Anorexia | 5 (20.0) |
| Melena | 11 (44.0) |
| Diarrhea | 11 (44.0) |
| Pertinent labs, mean ± SD | |
| Hemoglobin, mg/dL | 9.83 ± 2.3 |
| Albumin, g/dL | 3.38 ± 0.7 |
| C-reactive protein, mg/dL (n = 8) | 5.94 ± 4.6 |
| Vitamin B12 (n = 8) | 604.4 ± 353.6 |
| Endoscopy performed, no. of patients (%) | 25 (96.2) |
| Erythematous mucosa | 22 (88.0) |
| Erosions | 9 (36.0) |
| Ulcerations | 5 (20.0) |
| Edema | 13 (52.0) |
| Granularity | 5 (20.0) |
| Friability | 12 (48.0) |
| Atrophy | 1 (33.3) |
| Bleeding signs | 8 (32.0) |
| Focal inflammation | 9 (36.0) |
| Pathology available, no. of patients (%) | 16 (64.0) |
| Acute gastritis | 3 (12.0) |
| Chronic active gastritis | 6 (24.0) |
| Chronic inactive gastritis | 4 (16.0) |
| Reactive gastropathy | 3 (12.0) |
| Treatments, no. of patients (%) | |
| PPI | 24 (96.0) |
| Sucralfate | 10 (40.0) |
| Anti-nausea | 12 (48.0) |
| Prednisone | 9 (36.0) |
| Prednisone initial m, mg—median (Min-max) | 75 (20-80) |
| Immunotherapy continued after gastritis episode, no. of patients (%) | 13 (52.0) |
| Documented resolution or significant improvement in symptoms, No. of Patients (%) |
16 (64.0) |
Abbreviation: PPI, proton pump inhibitors.